Table 5 New or intensifying adverse effects in patients after dose escalation
New or intensifying adverse effects NDE = 22 | Number of patients (percent) | |||
|---|---|---|---|---|
Any grade | Grade 1 | Grade 2 | Grade 3 | |
All | 21 (95.5%) | 17 (77.3%) | 3 (13.6%) | 1 (4.5%) |
Fatigue | 9 (40.9%) | 7 (31.8%) | 2 (9.1%) | 0 |
Development / worsening of hypertension | 8 (36.4%) | 7 (31.8%) | 1 (4.5%) | 0 |
Stomatitis | 6 (27.3%) | 5 (22.7%) | 1 (4.5%) | 0 |
Diarrhea | 5 (22.7%) | 3 (13.6%) | 1 (4.5%) | 1 (4.5%) |
Weight loss 10%≤ | 4 (18.2%) | 4 (18.2%) | 0 | 0 |
Hand–foot syndrome | 4 (18.2%) | 4 (18.2%) | 0 | 0 |
Eyelid edema | 2 (9.1%) | 2 (9.1%) | 0 | 0 |
Hypothyroidism | 1 (4.5%) | 1 (4.5%) | 0 | 0 |
Elevation in creatinine level | 5 (18.2%) | 4 (18.2%) | 1 (4.5%) | 0 |
Thrombocytopenia | 4 (18.2%) | 2 (9.1%) | 2 (9.1%) | 0 |
Anemia | 3 (13.6%) | 2 (9.1%) | 1 (4.5%) | 0 |
Neutropenia | 2 (9.1%) | 1 (4.5%) | 1 (4.5%) | 0 |